Kenvue Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period. The report covers the fiscal three months ended April 2, 2023, compared with the three months ended April 3, 2022. Kenvue sells consumer health products through Self Care, Skin Health and Beauty, and Essential Health. These are unaudited combined financial statements for a business historically operated within Johnson & Johnson (J&J), with parent-company cost allocations; they may not represent costs as a standalone company.
Key financial results
| Metric | Q1 2023 | Prior-year quarter | Change |
|---|---|---|---|
| Net sales | $3.852 billion | $3.590 billion | +7.3%; organic growth +11.2% |
| Gross profit / margin | $2.125 billion / 55.2% | $1.956 billion / 54.5% | Margin +0.7 percentage points |
| Operating income / margin | $640 million / 16.6% | $611 million / 17.0% | Income +4.7%; margin down |
| Net income | $330 million | $528 million | Down 37.5% |
| Diluted EPS | $0.19 | $0.31 | Down $0.12 |
| Operating cash flow | $802 million | $338 million | Up $464 million |
| Investing cash flow | $(41) million | $(42) million | Primarily capital spending |
Organic sales growth reflected pricing, stronger cough, cold and allergy demand, supply replenishment, and easing supply constraints; unfavorable currency reduced reported sales growth by $141 million. Gross margin improved with sales mix and supply-chain savings, partly offsetting inflation in ingredients, freight, and packaging. SG&A rose 11.3% to $1.502 billion, including higher standalone-company, advertising, selling and distribution costs. Q1 separation-related costs were $98 million versus $10 million.
Segment performance
- Self Care: Sales $1.640 billion, up 11.9% reported and 15.3% organic; adjusted operating income $582 million, up 22.8%.
- Skin Health and Beauty: Sales $1.111 billion, up 9.8% reported and 13.2% organic; adjusted operating income $150 million, up 18.1%.
- Essential Health: Sales $1.101 billion, down 1.1% reported but up 4.0% organic; adjusted operating income $210 million, down 14.6%, primarily due to higher input costs.
Balance sheet, debt and liquidity
At April 2, 2023, cash and cash equivalents were $1.691 billion, restricted cash was $7.695 billion, and long-term debt was $7.676 billion. Restricted cash consisted principally of debt proceeds held in escrow for the business transfer, not funds available for current operations. Kenvue issued $7.75 billion of senior notes in March, with a 5.1% weighted-average effective interest rate; it had no borrowings under its $4.0 billion revolving facility or commercial paper program at quarter-end. It subsequently issued $1.25 billion of commercial paper before the IPO. Management said available cash, operating cash flow, borrowing capacity and capital-market access were expected to cover obligations for at least the next 12 months.
Operating cash flow increased partly because of working-capital movements, including timing of payments and lower inventories than in the prior-year quarter. The filing attributes the higher tax expense to a $171 million valuation allowance against deferred foreign tax credit benefits; the effective tax rate was 45.8%, versus 13.7%.
Separation, outlook and principal risks
J&J transferred substantially all Consumer Health Business assets and liabilities on April 4, 2023. Kenvue completed its IPO on May 8, 2023, selling 198.7 million shares at $22 per share and receiving approximately $4.2 billion net proceeds. It paid J&J $13.2 billion as partial consideration for the transfer. J&J retained approximately 89.6% ownership after the IPO and stated an intention to distribute some or all of its remaining stake, but is not obligated to do so. The filing provides no quantified earnings or sales guidance; it expects non-recurring separation costs to continue through at least fiscal 2024.
Key risks include competition and retailer concentration (one customer represented approximately 14% of quarterly sales; the top ten represented 42%), inflation and supply-chain disruption, foreign-currency and interest-rate exposure, product liability and regulatory matters, and costs or execution risks of becoming a standalone company. Legal matters include Tylenol-related claims, Zantac-related indemnification disputes, sunscreen litigation, and talc claims. J&J retained U.S. and Canadian talc-related liabilities and agreed to indemnify Kenvue for them; Kenvue remains responsible for relevant talc liabilities outside those countries. The filing says it cannot estimate possible losses beyond accrued amounts for certain matters. Management does not expect the ultimate outcome of legal proceedings, net of accruals, to materially affect financial position, but a resolution or increased accrual could materially affect results or cash flow in a period.
Most important facts for investors to verify
- Whether organic sales growth persists after one-time supply replenishment and respiratory-illness-driven demand, and how pricing affects volumes.
- Whether standalone costs, including separation expenses, and the elevated tax rate normalize; the filing gives no quantified forecast.
- Post-transfer debt, commercial paper usage, interest costs, and cash available after the $13.2 billion payment to J&J.
- Progress and terms of any J&J share distribution, and the continuing effects of J&J transition-service and other agreements.
- Developments in product-liability, Zantac, sunscreen, tax, and other legal matters, including indemnification coverage and potential cash exposure.